Peripheral Nerve Biology · Local Delivery · Global Development
Building the Future of Nerve Health
A nerve-focused therapeutic platform combining localized AAV delivery, clinical translation and a growing portfolio of programs across rare and large-market peripheral nerve disorders.
Nervosave is developing a new generation of therapies and treatments designed to act directly within peripheral nerves. Our lead program, NVO-101, is intended to establish the first clinical proof of the platform and unlock broader applications in neuropathic pain, auditory dysfunction and peripheral neuropathies.
Preclinical data presented on this site. Results may not translate directly to humans.
The Challenge
A Large and Growing Unmet Need in Nerve Health
Millions of people worldwide are affected by nerve disorders, chronic nerve pain, intensive digital use and age-related hearing loss. Current treatments are often insufficient, symptomatic or invasive, leaving a major unmet need.
CMT and other peripheral neuropathies
2.5 millionpatients worldwide with CMT
6–8%of adults in the US live with peripheral neuropathies (~20 million people)
50%require walking aids
Peripheral neuropathies, including CMT, cause progressive loss of sensation and motor function, leading to disability and reduced quality of life.
Neuropathic pain
~7–10%of the global population is affected by neuropathic pain (~600 million people)
Up to 50%of patients have inadequate pain relief with current treatments
Neuropathic pain can be chronic, severe and significantly impact daily life, sleep and mental health.
Esports and intensive computer users
37%of professional players reported hand, wrist or finger pain in surveyed esports populations
73%report overall pain in surveyed esports populations
~500 millionpeople worldwide are intensive players (gamers)
~3.5 billionpeople worldwide use computers and digital devices
Intensive and repetitive use of computers, smartphones and gaming devices can lead to upper-limb nerve strain and chronic symptoms.
Hearing and ageing
~10–20%of people with normal hearing tests show signs of hidden hearing loss (reduced neural function)
~25%of people over 60 experience a significant degree of hearing loss (>1.5 billion people worldwide)
Hidden hearing loss and age-related decline can affect communication, cognitive function and quality of life, with limited options today to prevent or restore auditory nerve function.
Detect. Evaluate. Predict. Prevent. And when nerve dysfunction becomes severe or persistent, treat the nerve itself — locally, safely and for the long term.
From rare neuropathies to chronic pain, nerve compression and nerve ageing.
The Platform
Local Delivery. Long-Lasting Nerve Biology
Nervosave combines a standard AAV9 vector with ultrasound-guided perineural administration to deliver therapeutic DNA directly to Schwann cells within peripheral nerves.
The objective is to turn the nerve into a localized therapeutic biofactory while limiting systemic exposure.
Mechanism of action — perineural AAV9 administration and Schwann-cell transduction
01
Ultrasound-guided perineural injection
Perineural injection is already used clinically in regional anaesthesia and provides direct access to peripheral nerves.
02
Standard AAV9 vector
The therapeutic construct is packaged in an established AAV9 vector.
03
Schwann-cell DNA delivery
Following local administration, AAV9 delivers DNA into Schwann cells surrounding peripheral axons.
04
Local therapeutic biofactory
Transduced Schwann cells produce the therapeutic payload inside the targeted nerve.
NVO-101 — siRNA strategyNVO-801 — locally produced therapeutic peptide
05
Long-lasting local benefit
The objective is sustained therapeutic activity within the nerve with limited off-target exposure.
Why Local Delivery Matters
Five Critical Platform Advantages
01
Direct Schwann-cell targeting
AAV9 efficiently transduces Schwann cells — the biological foundation of the platform.
02
Low systemic exposure
Local administration is designed to limit unnecessary vector exposure outside the targeted nerve.
03
Potential for redosing
Localized treatment and a potentially lower systemic immune response may create opportunities for repeat intervention.
04
Long-duration activity
Preclinical studies have shown prolonged activity after a single administration.
05
Clinically practical access
Ultrasound-guided perineural injection builds on a procedure already used routinely in regional anaesthesia.
Preclinical Validation
A Platform Built on Translational Evidence
>90%
Schwann-cell transduction
>30 cm
Diffusion along the nerve demonstrated in sheep
4 species
Validated in preclinical studies
≥12 months
Efficacy observed after a single injection in a CMT1A rat model
FDA Type B
Regulatory meeting completed for NVO-101
These data support the technological and regulatory foundation for the first clinical program and the broader platform.
Preclinical data. Results may not translate directly to humans.
Lead Program
NVO-101 The First Clinical Value Engine
NVO-101 is Nervosave's most advanced therapeutic program and is designed to provide the first human validation of the local nerve-delivery platform.
Charcot-Marie-Tooth disease type 1A — CMT1A
CMT1A is caused by duplication of the PMP22 gene, leading to abnormal Schwann-cell biology and progressive peripheral nerve dysfunction.
NVO-101 is designed to locally produce an siRNA specifically targeting PMP22 to reduce pathological PMP22 expression in Schwann cells following perineural administration.
Current development foundation
Validated in disease-relevant rodent models
Studied in larger species including sheep
FDA Type B meeting completed
Clinical team identified for a planned investigator-initiated study in China
Development path designed to progress from human proof of concept toward an IND-ready package
NVO-101 is not only a product candidate. It is intended to provide the first clinical validation of the broader Nervosave platform.
Clinical Strategy
Build Value Up To Clinical Proof
01
Pre-GMP manufacturing
02
Toxicology
03
Chinese IIT
04
Clinical proof of concept
05
IND-ready package
Initial financing and follow-on rounds are intended to advance NVO-101 through the critical development steps required to generate convincing human data.
Industry feedback indicates that pharmaceutical and biotechnology partners place substantial value on early human clinical validation before committing significant capital.
Primary partnering window: post-IIT / post-IND
Beyond NVO-101
From Clinical Proof to a Broad Nerve-Health Platform
NVO-101 is the starting point, not the end point.
A successful first clinical validation would establish the technological and regulatory foundation for a broader portfolio addressing much larger patient populations.
01 — NVO-101
First Clinical Validation
Rare neuropathy · CMT1A
The most advanced program is intended to validate:
efficient local nerve targeting
durable therapeutic activity
limited systemic exposure
clinically practical perineural administration
02 — Care-Esport + NVO-801
Build the Nerve-Care Model
Neuropathic pain · High-volume populations
Once the platform is clinically validated, Nervosave intends to expand into common, high-volume nerve disorders through an integrated care pathway.
NVO-801 represents the advanced therapeutic component for severe, persistent or refractory localized neuropathic pain, while CARE-ESPORT additionally provides a clinical and data layer for patient identification, monitoring and intervention.
03 — NVO-701
Auditory Nerve & Ageing
Future program
A future program targeting hearing-related nerve dysfunction, trauma-related damage, chemically induced dysfunction and age-associated auditory decline.
04 — NVO-301 / NVO-302
Broader Peripheral Neuropathies
Future programs
Future programs designed to extend the nerve-focused strategy into additional peripheral neuropathies and larger patient populations.
We start with an advanced rare-disease asset to generate the first clinical validation, then use that validation to unlock much larger global markets.
Clinical, Data & Performance Platform
Care-Esport A New Model for Nerve Care and Performance
CARE-ESPORT is designed to connect real-world patient access, quantitative assessment, nerve-performance monitoring and therapeutic intervention within a single nerve-health pathway.
Professional esports players represent an ideal initial population: they are exposed to intensive and repetitive upper-limb demands, depend on high levels of sensorimotor performance, and generate highly measurable functional outcomes.
CARE-ESPORT therefore aims not only to identify and manage nerve dysfunction, but also to understand how peripheral nerve health can be preserved — and potentially improved — to support sustained performance.
Step 01
Detect
Identify early nerve-related symptoms, functional changes and signs of declining nerve performance.
Step 02
Evaluate
Combine clinical assessment with objective measures of nerve function, sensorimotor performance and real-world activity.
Step 03
Predict
Develop models to identify individuals at increased risk of persistent dysfunction or performance decline.
Step 04
Prevent
Introduce ergonomic, behavioural and conservative interventions before functional deterioration or irreversible nerve damage develops.
Step 05
Improve Performance
Use individualized monitoring, rehabilitation and nerve-health interventions to optimize function, resilience and recovery in high-demand populations.
Step 06
Treat the Nerve
For severe, persistent or refractory dysfunction, provide advanced local therapeutic intervention targeting the nerve itself.
Esports is the entry cohort. The broader opportunity is to move from treating nerve dysfunction to preserving and improving nerve performance across much larger technology-intensive and ageing populations.
Global Execution
One Global Platform. Three Strategic Hubs
Nervosave is building a globally coordinated biotechnology platform by combining the complementary strengths of Europe, China and the United States.
The objective is not to duplicate capabilities across geographies, but to use the strongest ecosystem for each stage and each program.
🇫🇷
France / Europe
Science & Global IP
scientific foundation
platform biology
generation and management of intellectual property
global rare-disease programs
development outside licensed territories
coordination of the global portfolio
🇨🇳
China
Translational & Clinical Acceleration
investigator-initiated clinical studies
regulatory and clinical access
manufacturing partnerships
access to large patient populations
development of China-specific programs
local public-support and innovation ecosystem
🇺🇸
United States
Development & Commercialization
US regulatory and clinical expertise
access to leading clinical investigators
biotechnology capital markets
pharmaceutical and biotech partnerships
North American development and commercialization
One scientific platform. Multiple nerve disorders. Three complementary geographies. One globally coordinated value-creation strategy.
Global IP Strategy
Centralized Science. Regional Execution
Nervosave France
Global IP & Science Hub
Nervosave France coordinates the scientific platform and global intellectual-property strategy.
It controls the existing licensed academic intellectual property and is intended to own new proprietary patent applications arising from NVO-101 data and future platform developments.
New intellectual property is intended to support development across China, North America, Europe and other global markets.
China
Shensui / ChinaCo
Exclusive China development and exploitation rights, subject to final contractual arrangements.
North America
North American Development Vehicle
North American development and exploitation rights, subject to final corporate and licensing arrangements.
Regional Development Companies
Regional operating companies may receive territory-specific exploitation rights while remaining aligned with the global platform through licensing and equity participation.
Value Creation
Build. Validate. Partner. Reinvest.
Nervosave's objective is to create high-value clinical assets rather than independently finance full global development and commercialization of every program.
01
Build Clinical Value
Advance NVO-101 through manufacturing, toxicology and early clinical validation.
02
Monetize the Asset
Following compelling clinical data, seek a pharmaceutical or biotechnology transaction.
Preferred transaction structures
license of exploitation rights
regional licensing
global licensing
asset sale
broader corporate transaction
Potential economics
upfront payment
development and regulatory milestones
commercial milestones
royalties on future sales
03
Reinvest into the Platform
Use proceeds and validation from NVO-101 to accelerate the next generation of programs:
CARE-ESPORT + NVO-801
NVO-701
NVO-301 / NVO-302
One Platform. Multiple Assets. Repeated Value Creation.
Collaboration
Partnering Across the Value Chain
Nervosave's model is built around specialized partners rather than duplicating every capability internally.
We are interested in collaborations with organizations that can accelerate clinical validation, technology development and commercialization.
Clinical Centers
Investigator-initiated studies and translational research.
Gene-Therapy & CMC Specialists
Vector production, process development and manufacturing.
Academic Partners
Peripheral nerve biology and translational science.
Patient Organizations
Disease expertise, patient access and clinical-network development.
Pharmaceutical & Biotechnology Companies
Licensing, co-development and commercialization.
Digital-Health & Esports Organizations
Patient identification, longitudinal data and CARE-ESPORT deployment.
Strategic Investors
Capital aligned with clinical and geographic value-creation milestones.
Investors
Financing the First Human Validation
Nervosave is pursuing a capital-efficient development strategy centered on the clinical validation of NVO-101 and the establishment of regional execution capabilities.
Near-term capital is intended to support the operating team, intellectual property, manufacturing launch and preparation of the first China IIT.
